Health Condition 1: null- Myopic Choroidal Neovascular Memberane
Conditions
Interventions
Intervention1: Intravitreal Pegaptanib 0.3 mg: 0.3mg, every 6 weeks until visit 2(duration12 weeks).
Control Intervention1: No comparator agent, since this being single arm interventional study: No
Sponsors
LVPrasad Eye Institute
Omnicare Clinical Research Regulatory and Start Up Activities
Eligibility
Inclusion criteria
Inclusion criteria: 1.Should be willing to participate in the trial. 2.Age less than 55 years. 3.Best corrected visual acuity (BCVA) score of at least 5 letters (20/200), as assessed by ETDRS chart. 4.Myopia of greater than or equal to 6 Diopters. 5.Fluorescein angiographic documentation of CNV.
Exclusion criteria
Exclusion criteria: 1.Ocular causes, or other ocular disorders leading to vision loss. 2.Maculopathy not related to pathologic myopia. 3.Pregnancy, lactation. 4.Not willing to provide an informed consent. 5.History of previous macular laser including PDT. 6.Other forms of therapy including intravitreal injections. 7.History of intraocular surgery in the past 3 months. 8.Anticipated cataract surgery in the next 6 months. 9.Any active infection or inflammation in the eye. 10.Cases where good quality imaging is not possible, either due to hazy media or extremely high myopia. 11.Patients with uncontrolled glaucoma, with IOP 21mm Hg on 2 or more medications. 12.Patients with subfoveal scar or significant subretinal haemorrhage occupying more than 50% of lesion size. 13.Eyes with previous retinal detachment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mean change in visual acuityTimepoint: baseline to 54 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.Mean visual acuity 2. Mean change in macular thickness on OCT 3.3. Proportion of patients showing >0, 5, 10 and 15 letter gain and < 15 letter loss fromTimepoint: baseline to 54 weeks | — |
Countries
India
Contacts
Public ContactDrSridevi Rayasam
L.V.Prasad Eye Institute
Outcome results
None listed